Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 20 |
| Dec 2025 | 0 | 15 |
| Jan 2026 | 0 | 12 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 22 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2023 Filed Jun 22, 2023 20:30 UTC |
GLENN JOHNCHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Units · Derivative | 5,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010149 · form4-06222023_040601.xml · derivative · entry 3 GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,388 Underlying: Common Stock · 5,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 20, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On June 20, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:30 UTC |
GLENN JOHNCHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 1,412 | $47.88 | $67,606.56 |
DisclosureSEC source: 0001415889-23-010149 · form4-06222023_040601.xml · nonDerivative · entry 2 GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,883 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:30 UTC |
GLENN JOHNCHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 5,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010149 · form4-06222023_040601.xml · nonDerivative · entry 1 GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 21:48 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.36 | $473,552.00 |
DisclosureSEC source: 0000898432-23-000367 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 442,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.46 to $47.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 13:15 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $46.78 | $467,756.00 |
DisclosureSEC source: 0000898432-23-000365 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 452,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.46 to $47.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 15:02 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 4,175 | $46.31 | $193,354.69 |
DisclosureSEC source: 0000898432-23-000350 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 462,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.01 to $46.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 15:02 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 5,825 | $46.27 | $269,550.71 |
DisclosureSEC source: 0000898432-23-000350 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 467,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.27 to $47.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2023 Filed May 23, 2023 15:56 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $45.95 | $459,507.00 |
DisclosureSEC source: 0000898432-23-000328 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 472,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.22 to $46.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:04 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 3,258 | $45.32 | $147,659.73 |
DisclosureSEC source: 0000898432-23-000310 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 482,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:04 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 6,742 | $46.27 | $311,942.90 |
DisclosureSEC source: 0000898432-23-000310 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 486,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $47.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 10, 2023 20:58 UTC |
ALLEN MONTY KDirector
|
SaleCommon Stock | 2,786 | $46.03 | $128,232.34 |
DisclosureSEC source: 0000898432-23-000283 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,214 F1 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $46.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 15:49 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 7,521 | $46.50 | $349,712.21 |
DisclosureSEC source: 0000898432-23-000287 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 492,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $47.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2023 Filed May 11, 2023 15:49 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 2,479 | $48.04 | $119,081.74 |
DisclosureSEC source: 0000898432-23-000287 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 500,471 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.50 to $48.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2023 Filed May 8, 2023 22:40 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $46.20 | $461,976.00 |
DisclosureSEC source: 0000898432-23-000272 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 502,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $46.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 23:27 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $41.23 | $412,324.00 |
DisclosureSEC source: 0000898432-23-000213 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 512,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.96 to $41.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2023 Filed Apr 17, 2023 20:56 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $39.69 | $396,925.00 |
DisclosureSEC source: 0000898432-23-000202 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 522,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.32 to $40.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 16:09 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $40.26 | $402,577.00 |
DisclosureSEC source: 0000898432-23-000199 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 532,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.70 to $41.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 21:52 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $38.71 | $387,066.00 |
DisclosureSEC source: 0000898432-23-000198 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 542,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.37 to $39.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:41 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $38.11 | $381,082.00 |
DisclosureSEC source: 0000898432-23-000177 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 552,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.30 to $38.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 22:21 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $37.45 | $374,530.00 |
DisclosureSEC source: 0000898432-23-000165 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 562,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $38.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 14:35 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $37.81 | $378,117.00 |
DisclosureSEC source: 0000898432-23-000162 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 572,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.33 to $38.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 22:53 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 4,516 | $38.88 | $175,582.08 |
DisclosureSEC source: 0000898432-23-000151 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 582,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.52 to $39.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 22:53 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 5,484 | $38.52 | $211,243.68 |
DisclosureSEC source: 0000898432-23-000151 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 587,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.50 to $38.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 18:40 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 237 | $37.50 | $8,887.50 |
DisclosureSEC source: 0000898432-23-000127 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 592,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $37.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 18:40 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 9,763 | $37.79 | $368,943.77 |
DisclosureSEC source: 0000898432-23-000127 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 593,187 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.27 to $38.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 23:26 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $36.75 | $367,500.00 |
DisclosureSEC source: 0000898432-23-000119 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 602,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.37 to $37.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:04 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $35.50 | $355,000.00 |
DisclosureSEC source: 0000898432-23-000095 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 612,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.98 to $36.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:05 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $35.50 | $355,000.00 |
DisclosureSEC source: 0000898432-23-000092 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 612,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.98 to $36.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 21:01 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 2,000 | $35.60 | $71,200.00 |
DisclosureSEC source: 0000898432-23-000063 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,562 F1 · price: This transaction was executed in multiple trades all at $35.60. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 18:10 UTC |
GLENN JOHNChief Financial Officer
|
GrantCommon Stock | 2,500 | $28.67 | $71,675.75 |
DisclosureSEC source: 0000898432-22-000666 · form4.xml · nonDerivative · entry 1 GLENN JOHN · CIK 0001253497 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: This transaction was executed in multiple trades at prices ranging from $28.61 to $28.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC |
HAWKINS JAMES BDirector
|
GrantRestricted Stock Units · Derivative | 3,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537 Underlying: Common Stock · 3,501 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F4 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 Underlying: Common Stock · 1,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionCommon Stock | 1,035 | $28.56 | $29,559.60 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionCommon Stock | 2,037 | $28.56 | $58,176.72 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 17:33 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 5,000 | $28.58 | $142,905.50 |
DisclosureSEC source: 0000898432-22-000656 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,490 F2 · price: This transaction was executed in multiple trades at prices ranging from $28.48 to $28.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:24 UTC |
VUOTO ANTHONYDirector
|
GrantRestricted Stock Units · Derivative | 3,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000659 · form4.xml · derivative · entry 5 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537 Underlying: Common Stock · 3,501 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F5 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:24 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000659 · form4.xml · derivative · entry 4 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 Underlying: Common Stock · 1,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:24 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000659 · form4.xml · derivative · entry 3 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:24 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionCommon Stock | 1,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-22-000659 · form4.xml · nonDerivative · entry 2 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:24 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionCommon Stock | 2,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-22-000659 · form4.xml · nonDerivative · entry 1 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:18 UTC |
ALLEN MONTY KDirector
|
GrantRestricted Stock Units · Derivative | 3,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000657 · form4.xml · derivative · entry 5 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537 Underlying: Common Stock · 3,501 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F5 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000657 · form4.xml · derivative · entry 4 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 Underlying: Common Stock · 1,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000657 · form4.xml · derivative · entry 3 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 1,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-22-000657 · form4.xml · nonDerivative · entry 2 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:18 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 2,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-22-000657 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 15:43 UTC |
GLENN JOHNChief Financial Officer
|
GrantPerformance-based Restricted Stock Units · Derivative | 10,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000660 · form4.xml · derivative · entry 2 GLENN JOHN · CIK 0001253497 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,504 Underlying: Common Stock · 10,504 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025. F4 · derivative.exercise_date: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares. F5 · derivative.exercise_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested. F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025. F4 · derivative.expiration_date: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares. F5 · derivative.expiration_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 15:43 UTC |
GLENN JOHNChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 10,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000660 · form4.xml · derivative · entry 1 GLENN JOHN · CIK 0001253497 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,687 Underlying: Common Stock · 10,504 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 17:33 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 5,000 | $28.55 | $142,727.50 |
DisclosureSEC source: 0000898432-22-000656 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,490 F1 · price: This transaction was executed in multiple trades at prices ranging from $28.45 to $28.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 00:11 UTC |
VUOTO ANTHONYDirector
|
SaleCommon Stock | 1,000 | $28.55 | $28,547.40 |
DisclosureSEC source: 0000898432-22-000653 · form4.xml · nonDerivative · entry 1 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,121 F1 · price: This transaction was executed in a single trade at $28.5474. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.